NasdaqGS:TSHABiotechs
A Look At Taysha Gene Therapies (TSHA) Valuation After FDA Alignment On TSHA-102 BLA Pathway
Taysha Gene Therapies (TSHA) has reaffirmed FDA alignment on the Biologics License Application pathway for TSHA-102, including pivotal trial design and the potential use of a six month interim analysis for approval.
See our latest analysis for Taysha Gene Therapies.
The reaffirmed FDA pathway comes after a run in the stock, with a 30 day share price return of 45.95% and a 1 year total shareholder return of 217.62%. This signals strong momentum despite recent earnings losses and ongoing cash...